FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds possessing a high effectiveness in modulation of NMDA receptor activity.
EFFECT: compounds are applicable in treating the diseases and disorders, such as disturbed learning, cognitive activities, as well as for relieving and/or reducing neuropathic pain.
26 cl, 21 dwg, 2 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODULATOR OF NMDA-RECEPTOR WITH STABILISED SECONDARY STRUCTURE AND ITS USAGE | 2011 |
|
RU2566821C2 |
| NMDA RECEPTOR MODULATORS AND THEIR APPLICATION | 2012 |
|
RU2621049C2 |
| APPLICATION OF 2-(2-NITRO-4-TRIFLUORMETHYLBENZOYL)-1,3-CYCLOHEXANDIONE IN TREATMENT OF PARKINSON'S DISEASE | 2006 |
|
RU2420272C2 |
| COMBINATIONS OF COMPOUNDS MODULATING THE NMDA RECEPTOR | 2015 |
|
RU2721948C2 |
| NEMATOCIDAL SULPHONAMIDES | 2010 |
|
RU2531317C2 |
| SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | 2012 |
|
RU2569635C9 |
| β-LACTAMYL-SUBSTITUTED ANALOGUES OF PHENYLALANINE, CYSTEINE AND SERINE AS VASOPRESSIN ANTAGONISTS | 2006 |
|
RU2466991C2 |
| ARYL, HETEROARYL AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | 2018 |
|
RU2801278C2 |
| QUINAZOLINONE DERIVATIVES AND THEIR USE AS AGONISTS OF CANNABINOID (CB) RECEPTOR | 2003 |
|
RU2374235C2 |
| COMBINATIONS WHICH INCLUDE RECEPTOR S1P AGONIST AND JAK3 KINASE INHIBITOR | 2005 |
|
RU2415678C2 |
